Vilobelimab for Pyoderma Gangrenosum Earns Orphan Drug Designation
Source: https://pixabay.com/en/thumb-up-like-sign-hand-ok-good-441938/

Vilobelimab for Pyoderma Gangrenosum Earns Orphan Drug Designation

  At the end of June 2022, biopharmaceutical company InflaRx N.V. (“InflaRx”) shared via press release that its product vilobelimab recently earned Orphan Drug designation in both the United States…

Continue Reading Vilobelimab for Pyoderma Gangrenosum Earns Orphan Drug Designation
First Patient with HSCT-TMA Completes Nomacopan Treatment in Phase 3 Trial
Photo courtesy of Towfiqu Barbhuiya on Unsplash

First Patient with HSCT-TMA Completes Nomacopan Treatment in Phase 3 Trial

  On July 7, 2022, biotechnology company Akari Therapeutics, Plc ("Akari") shared via news release that the first patient in its clinical trial has completed their course of treatment. Within…

Continue Reading First Patient with HSCT-TMA Completes Nomacopan Treatment in Phase 3 Trial
Study Shows Keratoconus Patients Have Permanent Corneal Structure Changes If Unable to Get Timely Corneal Crosslinking
source: pixabay.com

Study Shows Keratoconus Patients Have Permanent Corneal Structure Changes If Unable to Get Timely Corneal Crosslinking

According to a recent article, a study has shown that keratoconus patients who do not get their timely corneal crosslinking will have permanent changes in their corneal structure.   Keratoconus…

Continue Reading Study Shows Keratoconus Patients Have Permanent Corneal Structure Changes If Unable to Get Timely Corneal Crosslinking
Rare Classroom: Gastroschisis
source: shutterstock

Rare Classroom: Gastroschisis

Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on some of the rarest, most…

Continue Reading Rare Classroom: Gastroschisis
Charcot-Marie-Tooth Disease: Theophylline Boosts Myelin Production in CMT1A Mice
source: unsplash.com

Charcot-Marie-Tooth Disease: Theophylline Boosts Myelin Production in CMT1A Mice

According to a story from Charcot-Marie-Tooth News, a recent study using a mouse model of Charcot-Marie-Tooth disease type 1A produced some interesting results. The researchers found that administration of theophylline…

Continue Reading Charcot-Marie-Tooth Disease: Theophylline Boosts Myelin Production in CMT1A Mice
ICYMI: Trabectedin for Ovarian Cancer Did Not Meet its Primary Endpoint
source: pixabay.com

ICYMI: Trabectedin for Ovarian Cancer Did Not Meet its Primary Endpoint

  Findings from the MITO23 Trial investigating the outcome of the chemotherapy drug trabectedin against physician’s choice to treat BRCA-mutated patients with ovarian cancer were presented at ASCO’s 2022 Annual…

Continue Reading ICYMI: Trabectedin for Ovarian Cancer Did Not Meet its Primary Endpoint
ICYMI: Evaluating Sogroya for Pediatric Growth Hormone Deficiency
source: unsplash.com

ICYMI: Evaluating Sogroya for Pediatric Growth Hormone Deficiency

  The ENDO 2022 Annual Congress took place from June 11-14, 2022. During the Congress, stakeholders met to discuss care, treatments, and research within endocrinology. In a news release from…

Continue Reading ICYMI: Evaluating Sogroya for Pediatric Growth Hormone Deficiency
ICYMI: His Doctors Finally Discovered the Cause of His Immune-Mediated Necrotizing Myopathy
source: pixabay.com

ICYMI: His Doctors Finally Discovered the Cause of His Immune-Mediated Necrotizing Myopathy

  The patient, age 82, had recovered from a stroke several months ago. According to a recent article reported on dnyuz.com and originally published in the New York Times, the…

Continue Reading ICYMI: His Doctors Finally Discovered the Cause of His Immune-Mediated Necrotizing Myopathy